anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During the administration of epidural anesthesia, it is recommended that a test dose of MARCAINE WITH EPINEPHRINE without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) be administered initially and the effects monitored before the full dose is given. When using a "continuous" catheter technique, test doses should be given prior to both the initial and all supplemental doses, because a catheter in the epidural space can migrate into a blood vessel or through the dura [see Dosage and Administration (2.4)].

During epidural administration, administer MARCAINE / MARCAINE WITH EPINEPHRINE, 0.5% (5 mg/mL) and MARCAINE 0.75% (7.5 mg/mL) solutions in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. Administer injections slowly, with frequent aspirations before and during the injection to avoid intravascular injection. Perform syringe aspirations before and during each supplemental injection in continuous (intermittent) catheter techniques. In obstetrics, use ONLY the 0.5% (5 mg/mL) and 0.25% (2.5 mg/mL) concentrations of MARCAINE / MARCAINE WITH EPINEPHRINE [see Warnings and Precautions (5.1)]; incremental doses of 3 mL to 5 mL of the 0.5% (5 mg/mL) solution not exceeding 50 mg to 100 mg at any dosing interval are recommended. Repeat doses should be preceded by a test dose containing epinephrine if not clinically contraindicated. Use only the single-dose vials for caudal or epidural anesthesia; avoid use of the multiple-dose vials for these procedures, which contain a preservative [see Dosage and Administration (2.1, 2.4), Warnings and Precautions (5.4, 5.9)].
A fully convolutional network (FCN) implemented on a specialized processor optimized for convolution computation can achieve a speed-up in cell classification. Without re-optimizing the specialized processor, a further speed-up is achieved by compacting a testing image of cells, and processing the compacted testing image with the FCN. The testing image is first segmented into a background and regions of interest (ROIs). The ROIs are packed closer together by rearranging the ROIs without resizing them under a constraint that any two adjacent rearranged ROIs are separated by a distance in pixel not less than a minimum distance determined according to stride values of FCN convolutional layers. Geometrical operations in ROI rearrangement include relocating the ROIs and, optionally, rotating the ROIs. The rearranged ROIs are enclosed by a boundary, typically a rectangular boundary, to form the compacted testing image having an area smaller than that of the testing image.
Despite its narrow therapeutic window, lithium is regarded as the gold standard comparator and benchmark treatment for mania. Attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using crystal engineering is underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (i.e. lithium salicylate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats. Remarkably, lithium salicylate produced elevated blood and brain levels of lithium beyond 48 hours post-dose without the sharp peak that contributes to the toxicity problems of current lithium therapeutics.
FIELD: medicine, allergology. SUBSTANCE: either hormonal or immunocorrecting preparations should be lymphotropically introduced due to subcutaneous injection. Injection area is mastoid processes from both sides and area of pretracheal fiber. Single dosage corresponds to 1/3-1/5 against average daily therapeutic dose. Therapy course lasts for 1-5 d. The suggested method enables to create high concentrations of medicinal preparation in pathological focus. EFFECT: higher efficiency of therapy. 4 ex
Active CTC assessment: Patients will receive first line docetaxel until progression by CTC, and/or disease progression according to treating clinician or completion of 10 cycles. CTC results will be available to the treating clinician to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 (-/+ 5 days) of that cycle. If a patient is found to have two successive CTC determinations showing progression by CTCs, the clinician will receive a recommendation to discontinue docetaxel on the following cycle.
The invention discloses a technical process for quantitatively describing accurate attenuation of myrobalan-processed kusnezoff monkshood root, belonging to the technical field of medicines. The Mongolian medicine prescription has high probability of using kusnezoff monkshood root, and kusnezoff monkshood root is used as the medicine after being processed by the myrobalan decoction. Aconitine alkaloid is the main active component of radix Aconiti Kusnezoffii and also the main toxic substance. Under the condition of room temperature, the aconitine in the kusnezoff monkshood root medicinal material can be dissolved in the myrobalan soup, and the content of the aconitine in the kusnezoff monkshood root medicinal material is reduced by repeatedly replacing the myrobalan soup. The fructus Chebulae decoction is acidic solution, and promotes transfer of aconitine type alkaloid. The dissolution of aconitine alkaloid in the myrobalan soup is the main reason for the reduction of the toxicity of the kusnezoff monkshood root medicinal material. The change of aconitine in chebula decoction conforms to the classic two-chamber kinetic model. The kinetic analysis provides a quantitative explanation basis for the precise attenuation preparation of Mongolian medicine, namely, kusnezoff monkshood root and myrobalan soup.
All participants will be randomly assigned to a 12-session group-based Mindfulness-Based Weight Control (MBWC) intervention or a Standard Behavioral Weight Control (SBWC) intervention. Participants assigned to the MBWC intervention will receive mindfulness curriculum informed by Mindfulness-Based Stress Reduction plus the standard behavioral weight control components. Group sessions will be approximately 60 minutes each week. Outside of group sessions, participants will be asked to engage in dietary self-monitoring (MBWC and SBWC groups) and practice mindfulness skills (MBWC only).
A gas permeable layer capable of supplying hydrogen includes a thin layer, encapsulating a hydrogen production formula. An outer side of the thin layer is airtight. An inner side is air-permeable. An inner side surface has a plurality of small holes. The thin layer can be a single layer or a composite layer. The hydrogen production formula does not dissipate. The hydrogen production formula absorbs moisture in the air or liquid water, thereby generating hydrogen. The hydrogen is released onto the skin and into the human body through the small holes. The hydrogen production formula includes metal peroxides, metal hydroxides, or metal hydrides and aluminum powder, or microsilica. The gas permeable layer can be used in sanitary products including eye masks, mouth masks, face masks, cosmetic facial masks, bras, pasties, nursing pads, sanitary napkins (towels), diapers, panty liners, wound dressing, woundplasts, bandage gauze, decubitus pads.
FIELD: veterinary science. SUBSTANCE: invention relates to method of preparing biologically active tissue preparation from placenta showing prophylactic and therapeutic effect in diseases of different etiology in agricultural animals. Method involves washing out placenta with purified water, preparing placenta homogenate, tissue hemolysis in purified water, the first fine tissue grinding in rotor-pulsator apparatus, disinfection and oxidation with 3% hydrogen peroxide solution, repeated treatment of semiproduct in rotor-pulsator apparatus, filtration and the ready product preparing. Preparation increases egg yield, gain weight of chicken-broilers, chickens hatching from incubator, enhances safety of carp this year's brood, increases additional gain weight of living mass in carps. EFFECT: improved method of preparing, enhanced effectiveness of preparation. 5 cl, 2 tbl
Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Reproduction studies have been performed in rats at doses up to at 1 MAC hour for a minimum of 21 days and have revealed no evidence of impaired fertility or harm to the fetus due to SUPRANE.

No teratogenic effect was observed at approximately 10 and 13 cumulative MAC-Hour exposures at 1 MAC-Hour per day during organogenesis in rats or rabbits. At higher doses increased incidences of post-implantation loss and maternal toxicity were observed. However, at 10 MAC-Hours cumulative exposure in rats, about 6% decrease in the weight of male pups was observed at preterm caesarean delivery.

Rats exposed to SUPRANE at 1 MAC-Hour per day from gestation day 15 to lactation day 21, did not show signs of dystocia. Body weights of pups delivered by these dams at birth and during lactation were comparable to that of control pups. No treatment related behavioral changes were reported in these pups during lactation.
INTRODUCTION: Malignant ascites indicates ovarian cancer progression and predicts poor clinical outcome. Various ascites components induce an immunosuppressive crosstalk between tumor and immune cells, which is poorly understood. In our previous study, imbalanced electrolytes, particularly high sodium content in malignant ascites, have been identified as a main immunosuppressive mechanism that impaired NK and T-cell activity.
METHODS: In the present study, we explored the role of high concentrations of ascites proteins and immunoglobulins on antitumoral NK effector functions. To this end, a coculture system consisting of healthy donor NK cells and ovarian cancer cells was used. The anti-EGFR antibody Cetuximab was added to induce antibody-dependent cellular cytotoxicity (ADCC). NK activity was assessed in the presence of different patient ascites samples and immunoglobulins that were isolated from ascites.
RESULTS: Overall high protein concentration in ascites impaired NK cell degranulation, conjugation to tumor cells, and intracellular calcium signaling. Immunoglobulins isolated from ascites samples competitively interfered with NK ADCC and inhibited the conjugation to target cells. Furthermore, downregulation of regulatory surface markers CD16 and DNAM-1 on NK cells was prevented by ascites-derived immunoglobulins during NK cell activation.
CONCLUSION: Our data show that high protein concentrations in biological fluids are able to suppress antitumoral activity of NK cells independent from the mechanism mediated by imbalanced electrolytes. The competitive interference between immunoglobulins of ascites and specific therapeutic antibodies could diminish the efficacy of antibody-based therapies and should be considered in antibody-based immunotherapies.
OBJECTIVE: The practice of simultaneous bilateral unicompartmental knee arthroplasty (SBUKA) remains a topic of debate, particularly in patients with obesity. Thus, the purpose of this study was to assess the impact of body mass index (BMI) on the 30-day complication rate and the survival rate of the implant following SBUKA.
METHODS: We retrospectively examined the clinical records of 245 patients (490 knees) who underwent SBUKA at the Affiliated Hospital of Qingdao University and the Third Hospital of Hebei Medical University between January 2010 and December 2020. Patients were categorised based on their BMI at the time of surgery into four groups: normal weight (BMI 18.5 to 22.9 kg/m2), overweight (BMI 23.0 to 24.9 kg/m2), obese (BMI 25.0 to 29.9 kg/m2), and severely obese (BMI ≥30 kg/m2). Variables such as length of hospital stay, duration of surgery, and costs of hospitalisation were compared across all groups. Additionally, we recorded the 30-day postoperative complication rate and the time from surgery to any required revision. The Kaplan-Meier survival analysis was employed to evaluate and compare the implant survival rates.
RESULTS: The follow-up period for the 245 patients ranged from 39 to 114 months, with an average of 77.05±18.71 months. The incidence of complications within 30 days post-surgery did not significantly differ across the groups (χ2 = 1.102, p = 0.777). The implant survival rates from the lowest to the highest BMI groups were 97.14%, 93.9%, 94.44%, and 96.43%, respectively. Both the rate of implant revision (χ2 =1.612, p = 0.657) and the survival curves of the implants (p = 0.639) showed no statistically significant differences among the groups.
CONCLUSIONS: BMI did not influence the 30-day complication rate nor the survival rate of implants following SBUKA, suggesting that SBUKA should not be contraindicated based on BMI alone.
PURPOSE:To obtain a high purity water soluble chitosan salt in an industrially easy manner by reacting an acid with a solid chitosan in a polar organic solvent. CONSTITUTION:A chitosan salt is obtained by reacting an acid with a solid chitosan in a polar organic solvent. An example for chitosan is one obtained by deacetylating chitin by treatment with a concentrated alkali. Examples of the chitin includes alpha-chitin obtained from Crustacea such as crab or lobster and beta-chitin obtained from Mollusks such as cattle fish. As the solid chitosans used, those in the form of particles or a powder are desirable, and particularly one obtained by deacetylating pulverized chitin is desirable. The pulverization of the starting chitin is desirably performed by pulverizing it to about 80 mesh or smaller with a pulverizer such as a ball mill or a hammer mill.
<P>PROBLEM TO BE SOLVED: To improve efficiency in the job of pharmacists by designating a pharmacist in charge of the next time.  <P>SOLUTION: Post-calculation is instructed through an input part 32 at a portable terminal 30a. When a patient of a post calculation object is selected, it is judged whether a pharmacist authenticated based on past teaching data of the selected patient is the pharmacist designated as the pharmacist in charge of the next time. When the authenticated pharmacist is the designated pharmacist, processing is shifted to post-calculation processing to carry out data processing for display of prescription data received this time and charge calculation of medicine preparation management charge etc. When the authenticated pharmacist is not the designated pharmacist, a warning message that the pharmacist in charge of the next time is designated to another pharmacist is displayed on a display part 33, and carrying out of post-calculation processing of the patient is restricted. When release of designation is instructed in addition, the designation of the pharmacist in charge is released to carry out post-calculation processing.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention discloses an application of PMX-53 polypeptide in preparing a medicament for treating non-alcoholic steatohepatitis. After the treatment with PMX-53 inhibitor, the number of lipid droplets in the liver cells of NASH mice is reduced, the lipid droplets become small, and the liver fat becomes obviously reduced, as can be seen from H & E and oil red O staining graphs (FIG. 3A); the quantitative PCR result shows that the expression of the fat synthesis related genes Srebf1, Acc and Fasn is remarkably reduced (figure 3B), and further confirmed by WB, the result of figure 3C shows that the fat synthesis related proteins Acc and Fasn are reduced in the liver tissue of the mouse; quantitative PCR and ELISA assays showed significant down-regulation of the expression of the inflammation-associated factors IL-6 and TNF-. alpha. (FIGS. 3D and E). These results show that the C5ar1 specific inhibitor PMX-53 treatment can reduce mouse non-alcoholic steatohepatitis, so that PMX-53 can be applied to the preparation of drugs for treating non-alcoholic steatohepatitis.
Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
For participants randomized to SAT, consistent with stepped care, treatment will begin with lower intensity services that are stepped up, if necessary, at a predefined time point. Step 1 consists of three motivational interviewing (MI)sessions delivered every 2 weeks. At the 3-month assessment, those with non-response to MI, defined as continued unhealthy alcohol use in the prior 14 days, will be referred to on site physician managed addiction specialty services (Step 2) for higher intensity services.
An azatetracyclic carbonitrile compd.(I) and its acidaddition salt, used as pharmaceutical agents, are prepared from reactive diesters of diethanol(II) by means of reaction with compd.(III), of which the chemical formula is H-NR-H, or from compd. (IV) by means of reaction with a cyanated compd., where R = H, lower alkyl, or C4-C8 cycloalkyl-lower alkyl; and Hal = halogen atom such as Cl, I, or Br. Suitable cyanated compds. are alkali metal cyanate or heavy metal cyanate.
XENAZINE may increase the risk of akathisia, restlessness, and agitation.

In a 12-week, double-blind, placebo-controlled study in patients with chorea associated with HD, akathisia was observed in 10 (19%) of XENAZINE-treated patients and 0% of placebo-treated patients. In an 80-week, open-label study, akathisia was observed in 20% of XENAZINE-treated patients. 

Patients receiving XENAZINE should be monitored for the presence of akathisia. Patients receiving XENAZINE should also be monitored for signs and symptoms of restlessness and agitation, as these may be indicators of developing akathisia. If a patient develops akathisia, the XENAZINE dose should be reduced; however, some patients may require discontinuation of therapy.
Methods and apparatus for laser treating batches of pharmaceutical dispensers are provided. Sequential batches of untreated dispensers are carried on alternate batch carriers that are advanced into associated alternate stationary laser treatment stations. The multiple stationary laser treatment stations are located within a region of adjacency in which a single laser source can be operated to treat alternate batches of dispensers positioned within the associated alternate laser treatment stations. A laser controller directs the laser beam to alternatingly operate in each laser treatment station and, within each laser treatment station, to treat each dispenser in a batch of dispensers positioned therein. An advance coordinator advances the batch carriers in coordination with the activity of the laser controller in a repeating alternating cycle wherein one batch of untreated dispensers is held stationary in position within one laser treatment station (while the laser is operated in the one laser treatment station) during the time  that another batch of untreated dispensers is being advanced into another laser treatment station. In this manner, a batch of untreated dispensers is substantially continuously positioned in one or another laser treatment station and the laser is optimally substantially continuously operating to treat dispensers within one or another of the laser treatment stations.
The aim of this project is to evaluate the efficacy of preoperative erector spinae blocks in arthroscopic hip surgery. This will be a prospective randomized controlled trial. The control group will not receive a preoperative block prior to surgery, but will receive local anesthetic at the surgical site at the conclusion of the surgery. The study group will receive a preoperative block and local anesthetic. The primary outcomes will be pain levels and opioid consumption in the post-operative care unit. The secondary outcomes will be pain levels and opioid consumption post-operatively, and functional outcome measures.
Riboflavin drops are used every 2 minutes for 30+ minutes until the corneal stroma is saturated with Riboflavin as evidenced by observing Riboflavin in the Anterior chamber. Two arms in the study, one uses Riboflavin with Epithelium on and the other with Epithelium off. Once it is observed that the Riboflavin has penetrated the stroma and is seen in the anterior chamber, the cornea is exposed to Ultraviolet light at an irradiance level of 18mW/cm2 for 5 minutes. A contact lens is applied until the epithelium has fully healed in 3 to 5 days. The study is for 6 months. The corneal curvature as well as the uncorrected and best corrected vision and corneal thickness are evaluated pre-operatively and at 6 months. The primary variable that is assessed to determine the efficacy of the drug is the Kmax - Steep corneal curvature. Secondary effectiveness criteria are uncorrected and best corrected vision and corneal thickness. adverse events are also monitored.
To systematically review studies evaluating pharmacological treatment intervention of the atypical antipsychotic induced weight gain in the pediatric population and summarize the current evidence of the pharmacological treatment. According to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, we searched the various databases Medline, PubMed, PubMed central (PMC), CINAHL, and clinicaltrial.gov. until Jan 30th, 2022 for relevant clinical studies. Medical subject heading (MeSH) terms or keywords were used, "Body Weight," "Weight Gain," "Weight Loss," "Body Weight Maintenance," "Pediatric Obesity" in "Pediatrics," "Adolescent," "Child" in context of "Antipsychotic Agents" and "Drug Therapy," "Therapeutics," "Treatment Outcome," "Early Medical Intervention." We used the PICO algorithm for our search (Population, Intervention, Comparison, Outcomes, and Study Design) framework. The initial search included 746 articles, nine studies were ultimately selected in the final qualitative review. We included relevant clinical reviews, case series, and randomized clinical trials that evaluated pharmacological intervention for antipsychotic-induced weight gain in the pediatric population. Non-peer-reviewed, non-human, non-English languages article was excluded. Metformin is the most studied medication for antipsychotic-induced weight gain in children. Three studies have shown that adding Metformin to the antipsychotics can significantly reduce the body weight and body mass index with mild transient side effects. Other adjunct medications like topiramate, amantadine, betahistine, or melatonin vary greatly in mitigating weight with various side effects. Lifestyle modification is the first step in dealing with AIWG, but the result is inconsistent. Avoiding the use of antipsychotic in children is preferred. Adding an adjuvant medication to the antipsychotic could prevent or mitigate their negative metabolic effect on the body weight and body mass index. Metformin has the most evidence, topiramate, betahistine, amantadine, and melatonin is possible alternatives in the pediatric patient without changing their antipsychotic medication. Other viable options show some benefits but need further clinical studies to establish efficacy and safety.